Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication by van der Meer AJ, Feld JJ2, Hofer H3, Almasio PL, Calvaruso V, Fern&#225
Research ArticleRisk of cirrhosis-related complications in patients with
advanced fibrosis following hepatitis C virus eradication
Adriaan J. van der Meer1,⇑, Jordan J. Feld2, Harald Hofer3, Piero L. Almasio4, Vincenza Calvaruso4,
Conrado M. Fernández-Rodríguez5, Soo Aleman6,7, Nathalie Ganne-Carrié8, Roberta D’Ambrosio9,
Stanislas Pol10, Maria Trapero-Marugan11, Raoel Maan1, Ricardo Moreno-Otero11, Vincent Mallet10,
Rolf Hultcrantz6, Ola Weiland7, Karoline Rutter3, Vito Di Marco4, Sonia Alonso5, Savino Bruno12,
Massimo Colombo9, Robert J. de Knegt1, Bart J. Veldt1, Bettina E. Hansen1, Harry L.A. Janssen1,2
1Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands; 2The
Toronto Centre for Liver Disease, University Health Network, Toronto, Ontario, Canada; 3Department of Internal Medicine III,
Division of Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria; 4Gastrointestinal & Liver Unit,
Dipartimento Biomedico di Medicina Interna e Specialistica, University of Palermo, Palermo, Italy; 5Unit of Gastroenterology and Liver
Diseases, University Hospital Fundación Alcorcón, Madrid, Spain; 6Departments of Gastroenterology and Hepatology, Karolinska Institutet at
Karolinska University Hospital, Stockholm, Sweden; 7Karolinska University Hospital Huddinge, Karolinska Institutet, Stockholm, Sweden;
8Unité d’Hépatologie, APHP Hôspital Jean Verdier, Université Paris 13, Inserm UMR 1162, France; 9A.M. and A. Migliavacca Center for Liver
Disease, First Division of Gastroenterology, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Università degli Studi di Milano, Milan,
Italy; 10Unité d’Hépatologie, APHP Hôpital Cochin, Université Paris Descartes, Inserm U1016, Paris, France; 11Gastroenterology-Hepatology
Department, University Hospital La Princesa and Princesa Research Institute, Autonomous University of Madrid, Madrid, Spain; 12Department
of Internal Medicine, Humanitas University and IRCCS Istituto Clinico Humanitas, Rozzano (Milan), ItalyBackground & Aims: The risk of hepatocellular carcinoma (HCC) Multivariable Cox analyses indicated that higher age, lower platelet
is reduced but not eradicated among patients with hepatitis C count and diabetes mellitus were independently associated with
virus (HCV)-induced advanced hepatic fibrosis who attained sus-
tained viral response (SVR). We aimed to assess the risk of
cirrhosis-related complications in this specific group of patients.
Methods: Data from previously reported Western cohort studies
including patients with chronic HCV infection and bridging fibro-
sis or cirrhosis who attained SVR were pooled for survival analy-
ses on the individual patient level. The primary endpoint was
HCC and the secondary endpoint was clinical disease progression,
defined as liver failure, HCC or death.
Results: Included were 1000 patients with SVR. Median age was
52.7 (IQR 45.1–59.7) years, 676 (68%) were male and 842 (85%)
had cirrhosis. Median follow-up was 5.7 (IQR 2.9–8.0) years.
Fifty-one patients developed HCC and 101 had clinical disease
progression. The cumulative 8-year HCC incidence was 1.8 (95%
CI 0.0–4.3) among patients with bridging fibrosis and 8.7% (95%
CI 6.0–11.4) among those with cirrhosis (p = 0.058). Within the
cirrhosis group, the 8-year HCC incidence was 2.6% (95% CI
0.0–5.5) among patients <45 years, 9.7% (95% CI 5.8–13.6) among
patients from 45–60 years, and 12.2% (95% CI 5.3–19.1) among
patients >60 years of age at start of therapy (p = 0.006).Journal of Hepatology 20
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E-mail address: a.vandermeer@erasmusmc.nl (A.J. van der Meer).development of HCC. After 8 years 4.2% (95% CI 0.1–8.3) of patients
with bridging fibrosis and 15.8% (95% CI 12.3–19.3) of patients with
cirrhosis experienced clinical disease progression (p = 0.007).
Conclusions: Patients with HCV-induced cirrhosis and SVR
showed an annual risk of approximately 1% for HCC and 2% for
clinical disease progression. Therefore, to prevent HCC surveil-
lance, chronic HCV infection should preferably be treated before
cirrhosis has developed.
Lay summary: Patients with cirrhosis who were able to eradicate
their chronic HCV infection remain at substantial risk of primary
liver cancer. The risk of liver cancer increases with higher age,
laboratory makers suggesting more severe liver disease, and
presence of diabetes mellitus. Also after successful antiviral ther-
apy patients with HCV-induced cirrhosis should thus remain
included in follow-up for early detection of liver cancer.
 2016 European Association for the Study of the Liver. Published
by Elsevier B.V. All rights reserved.Introduction
Chronic infection with the hepatitis C virus (HCV) may lead to the
development of hepatic fibrosis, which can ultimately progress to
cirrhosis. Patients with cirrhosis have an increased risk to develop
end-stage liver disease and hepatocellular carcinoma (HCC) [1]. A
recent meta-analysis found that chronic HCV-infected patients
with advanced hepatic fibrosis had an overall annual risk of 2.9%
to experience liver failure, 3.2% to develop HCC and 2.7% to die17 vol. 66 j 485–493
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of liver-related causes [2]. According to the current guidelines
these patients should be included in HCC surveillance programs
[3,4]. In the forthcoming years, there will be an increase in the
incidence of HCV-induced cirrhosis and its clinical complications
in the Western world [5,6]. In fact, in the USA it is estimated that
by 2030 almost half of the population with chronic HCV infection
will have cirrhosis [5].
Antiviral therapy has been available since the early 1990s and
is usually considered successful when a sustained virological
response (SVR), defined as HCV RNA negativity 12 or 24 weeks
after cessation of treatment, is attained. However, SVR rates have
been disappointing with the interferon (IFN)-based regimens,
especially among patients with advanced liver disease [7]. Even
for this important subgroup of patients, however, the efficacy of
antiviral therapy has improved tremendously due to the develop-
ment of direct-acting antiviral drugs. Recently, various IFN-free
regimens have actually showed cure rates well over 90 percent
among patients with chronic HCV infection and bridging fibrosis
or cirrhosis. Another advantage of these new treatment regimens
concerns the good safety-profile, which should lead to an increase
in treatment uptake. In the end, treatingmore patients is essential
if we really want to reduce HCV-related morbidity and mortality
[8]. Institution of HCV screening programs, such as birth-cohort
screening in the USA, should therefore be considered as a major
accomplishment as well [9,10].
Both the antiviral treatment improvements and implementa-
tion of screening for HCV infection are likely to increase the pop-
ulation with HCV-induced cirrhosis and SVR. Several studies have
shown that the incidence of liver failure and HCC is markedly
lower among patients with cirrhosis and SVR as compared to
those without SVR [11–15]. However, these studies also indicated
that the risk of HCC was not entirely eradicated even when the
HCV infection was cured. Case reports have even described
patients who were diagnosed with HCC up to 13 years following
successful antiviral therapy [16]. To date, risk factors of HCC fol-
lowing SVR are largely unknown. Despite respectable follow-up
durations, prior Western cohort studies did not include sufficient
patients with SVR and HCC for subgroup analyses. This can be
attributed to the low rate of SVR with IFN-based regimens among
patients with cirrhosis as well as the low risk of cirrhosis-related
complications following HCV eradication.
Here we present the results of a study which aimed to assess
the risk of HCC, as well as liver disease progression in general,
among Western patients with chronic HCV infection and
advanced hepatic fibrosis following achievement of SVR. We also
studied the baseline factors which were associated with these
outcomes in this specific population.Patients and methods
The primary investigators of previously reported European and Canadian-based
cohort studies including patients with chronic HCV infection and advanced hep-
atic fibrosis were invited to participate in the current study based on individual
patient data [11,12,14,15,17–24]. All patients with bridging fibrosis or cirrhosis
were eligible for inclusion if they had attained SVR with an IFN-based antiviral
treatment regimen and if there was available follow-up data. Patients co-
infected with human immunodeficiency virus or hepatitis B virus were excluded.
The datasets of the original retrospective cohort studies based on chart
review were sent to a single investigator (AJM), who monitored and entered
the data into a uniform database system. In case of any doubt regarding the vari-
ables in the original dataset, the principal investigator of the participating cohort
was contacted to answer any queries before incorporating the data into the cen-
tral database.486 Journal of Hepatology 201We collected all available information on patient demographics (sex, age,
body mass index [BMI]), stage of liver disease (bridging fibrosis or cirrhosis),
antiviral treatment (type of IFN used), presence of diabetes mellitus (DM), a his-
tory of severe alcohol use, virology (HCV genotype, anti-hepatitis B core antigen
[antiHBc] status) and start-of-treatment laboratory parameters (platelet count,
bilirubin, albumin, aspartate aminotransferase [AST], alanine aminotransferase
[ALT], gamma-glutamyltransferase [gGT]). Cirrhosis was determined by either
histopathological assessment of liver biopsy, transient elastography, or clinical
judgement at the discretion of the treating physician based on a combination
of biochemical parameters, clinical signs of portal hypertension and/or radiologic
findings consistent with cirrhosis.
The study was conducted in accordance with the guidelines of the Declara-
tion of Helsinki and the principles of Good Clinical Practice. All original study pro-
tocols had been reviewed and approved by the local ethics committees, and the
results of all these studies have been published in the international literature.
Informed consent had previously been obtained according to the local regulations
of the participating centers in the original cohort studies.
Clinical events
The primary outcome of the study was development of HCC. Clinical disease pro-
gression was the secondary endpoint, which was defined as the occurrence of
either HCC, liver failure, liver transplantation or mortality. In case multiple events
occurred in a single subject, only the first event contributed to this combined clin-
ical outcome measure.
In accordance with international guidelines, the diagnosis of HCC was based
on histopathological confirmation or two coincident imaging techniques (com-
puted tomography, magnetic resonance imaging or contrast-enhanced ultra-
sonography) showing a focal lesion larger than 2 cm with arterial-phase hyper
enhancement or one imaging technique showing a focal lesion larger than 2 cm
with arterial-phase hyper enhancement in the presence of an a-fetoprotein level
greater than 400 ng/ml [25]. Liver failure was defined as an episode of either
ascites, bleeding varices, jaundice or hepatic encephalopathy. Death was classified
as liver-related or not liver-related. In general, death is considered liver-related in
case this is due to end-stage HCC or because of deteriorating liver function, but
was at the discretion of the treating physician who collected the data.
Statistical analysis
Follow-up started 24 weeks after the end-of-treatment, which was defined as
time 0, since patients with undetectable HCV RNA at this time point were classi-
fied as having attained SVR. Patients who were diagnosed with HCC or patients
who were lost to follow-up prior to 24 weeks after the end-of-treatment were
not included in the analyses. In the survival analyses regarding clinical disease
progression, patients who were diagnosed with HCC or who experienced liver
failure prior to 24 week after the end-of-treatment were excluded. Patients were
censored at their last date of follow-up.
The Kaplan-Meier method was used to assess the cumulative incidence of
clinical events during follow-up, and differences according to categorical vari-
ables were assessed by the log-rank test. Univariable and multivariable Cox
regression analyses were performed to assess which baseline variables were asso-
ciated with the occurrence of clinical events. The proportionality assumption was
checked by assessing if the effect of the variables on the outcome was changing
over the log-transformed follow-up time for both continuous and categorical
variables. Our multivariable models were constructed by considering all variables
with a p value <0.1 in univariable analysis in a stepwise backward selection
approach. Hereafter the variables outside of the model were introduced one-
by-one to assess for possible confounding. The decision to keep the AST/ALT ratio
in the model for HCC was made afterwards because of the borderline statistical
significance, the effect size, and the biological plausibility of the association. As
the period of inclusion was rather long, the analyses were stratified for the med-
ian year of inclusion. Adjustment for the type of IFN was considered as the chance
of SVR is higher with pegylated (Peg)IFN as opposed to IFN. Because the hazard
ratios of the variables in the model for HCC did hardly change by inclusion of
the type of IFN, while this did result in overparameterization due to the limited
number of HCC events, we decided to refrain from adjusting for type of IFN in
the analyses of HCC.
The primary analyses concerned complete-case analyses. As a result of differ-
ences in data collection among the participating cohort studies, entire cohorts
could drop out of the multivariable analyses in case the included baseline
variables were not available. As sensitivity analyses, multiple imputation to
impute missing values was performed with the iterative random number-based
Markov Chain Monte Carlo method assuming multivariate normality with7 vol. 66 j 485–493
Table 1. Baseline characteristics.*
Overall
(n = 1000)
Age, years, median (IQR)# 52.7 (45.1–59.7)
<45 years 241/998 (24)
45–60 years 526/998 (53)
>60 years 231/998 (23)
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non-informative prior to using the SAS Proc MI package, by which 10 complete
datasets were constructed in order to check the stability of the final multivariable
Cox regression models.
All statistical tests were two-sided, and a p value <0.05 was considered to be
statistically significant. The significance level for interactions was set at p = 0.01
to correct for multiple testing. SPSS version 22.0.1 (SPSS Inc., Chicago, IL, USA)
and SAS 9.3 PROC GENMOD (SAS institute, Cary, NC, USA) were used for all
statistical analyses.Males 676/1000 (68)
BMI, kg/m2, median (IQR)¥ 25.7 (23.3–28.4)
BMI >28 211/752 (28.1)
Disease stage
Bridging fibrosis 153/995 (15)
Cirrhosis 842/995 (85)
HCV genotype
1 459/918 (50)
2 220/918 (24)
3 181/918 (20)
4 49/918 (5)
Other 9/918 (1)
Type of treatment
IFN (± ribavirin) 294/997 (30)
PegIFN (± ribavirin) 701/997 (70)
consensus IFN (+ ribavirin) 2/997 (<1)
Laboratory markers of liver disease severity, median
(IQR)£
Platelet count, 109/L 150 (116–194)
Albumin, g/L 42 (39–44)
Bilirubin, mmol/L 13.7 (10.3–17.1)
AST/ALT ratio 0.72 (0.57–0.90)
gGT, IU/L 56 (34–98)
Treatment naïve, n/of total (%) 624/972 (64)
Year treatment started– 2002 (1999–
2005)
Diabetes mellitus, n/of total (%) 117/819 (14)
History of severe alcohol use, n/of total (%) 128/575 (22)
AntiHBc positive, n/of total (%) 198/643 (31)
ALT, Alanine aminotransferase; antiHBc, anti-hepatitis B core antigen; AST,
aspartate aminotransferase; BMI, body mass index; gGT, gamma-glutamyltrans-
ferase; HCV, hepatitis C virus; IQR, interquartile range; IFN, interferon; PegIFN,
pegylated interferon.
*Data are presented as No./Total No. (%) unless otherwise noted.
#Age was available in 998 (100%) patients.
¥BMI was available in 642 (64%) patients. One of the participating cohorts had
collected data on BMI as a categorical variable (BMI 628 kg/m2 or >28 kg/m2), so
that more data was available when BMI was categorized according to the 28 kg/
m2 cut-off.
£Platelet count was available in 955 (96%) patients, albumin in 808 (81%)
patients, bilirubin in 813 (81%) patients, AST/ALT ratio in 801 (80%) patients and
gGT in 700 (70%) patients.
–The year treatment started was available in 991 (99%) patients.Results
Study population
In total, 1000 patients with advanced hepatic fibrosis who had
attained SVR were analysed from previously reported HCV treat-
ment cohorts with long-term follow-up [11,12,14,15,17–24]
(Supplementary Table 1). The median age was 52.7 years
(interquartile range [IQR] 45.1–59.7) and 676 (68%) patients were
male. Cirrhosis was present in 842 (85%) patients, others were
classified as having bridging fibrosis. The stage of liver disease
was based on liver histology in 896 (90%) patients and on tran-
sient elastography, presence of esophageal varices, and/or clinical
judgement in 83 (8%) patients. For 21 (2%) patients data regard-
ing the diagnostic modality on which the stage of liver disease
was based was not available. Table 1 describes all baseline vari-
ables. The majority of patients were treated with a PegIFN-
based regimen (n = 701, 70%). In five (<1%) patients a protease
inhibitor was added. The year that successful antiviral therapy
was initiated ranged from 1987 to 2010 (median 2002 [IQR
1999–2005]). Patients were followed for a median duration of
5.7 years (IQR 2.9–8.0).
Hepatocellular carcinoma
During follow-up, 51 patients were diagnosed with HCC, which
resulted in a HCC rate of 0.90 per 100 person-years (95% confi-
dence interval [CI] 0.67–1.18) (Table 2). The time interval
between SVR and the diagnosis of HCC ranged from 0.2 to
11.8 years (median 5.8 years, IQR 2.6–7.4). The median age at
the time of HCC was 65 years (IQR 57–69). The overall cumulative
8-year HCC incidence was 7.6% (95% CI 5.2–10.0). The cumulative
8-year HCC incidence was markedly higher among patients with
cirrhosis (8.7%, 95% CI 6.0–11.4) as compared to patients who
were classified as having bridging fibrosis (1.8%, 95% CI 0.0–4.3)
(Fig. 1). Among patients with cirrhosis, those below the age of
45 at the start of therapy showed a cumulative 8-year HCC rate
of 2.6% (95% CI 0.0–5.5), while this was 12.2% (95% CI 5.3–19.1)
among patients above 60 years of age (Fig. 2). Three of the 158
(2%) patients classified as having bridging fibrosis were diag-
nosed with HCC after 3.1, 3.9 and 9.8 years following achieve-
ment of SVR. All were around 60 years of age at the start of
therapy. None had DM at baseline and their BMI ranged from
23.3 to 25.8. The first two patients had no history of alcohol
abuse, but data on alcohol use was not available for the third
patient. Their baseline platelets ranged from 127 to 166  109/L.
Table 3 shows the results of the Cox regression analyses
regarding HCC occurrence among the total group of patients. Sig-
nificantly associated with HCC in univariable analyses were
higher age, lower platelet count, higher AST/ALT ratio, and prior
unsuccessful antiviral therapy. Gender did not influence the risk
of HCC (p = 0.426). In multivariable analyses, the platelet countJournal of Hepatology 201remained an independent predictor of HCC. Although the HR of
the AST/ALT ratio (HR 1.04, 95% CI 1.00–1.09, p = 0.084) remained
similar to that in univariable analysis, the association between
the AST/ALT ratio and HCC fell just outside of the pre-specified
significance level in the multivariable Cox model. Adjusted for
age and the laboratory markers of liver disease severity, the asso-
ciation between DM was statistically significant (HR 2.36, 95% CI
1.02–5.42, p = 0.044). When added to the final model, being treat-
ment naïve was no longer significantly associated with HCC (HR
0.71, 95% CI 0.34–1.48, p = 0.363). The proportional hazard
assumptions were met and there were no statistically significant
interactions between the variables included in the final model.
Following imputation of missing data, which was performed as
a sensitivity analysis, the estimated HRs were similar (Table 3).7 vol. 66 j 485–493 487
Table 2. Event rate per 100 person-years.
Events
No.
Observation
period,
person-years
Rate/100
person-years
(95% CI)
Hepatocellular carcinoma 51 5671 0.90 (0.67–1.18)
Liver failure 26 5664 0.46 (0.30–0.67)
All-cause mortality 56 5750 0.97 (0.74–1.26)
Clinical disease progression 101 5592 1.80 (1.47–2.20)
CI; confidence interval.
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Fig. 1. Incidence of hepatocellular carcinoma following sustained virological
response according to the presence of bridging fibrosis or cirrhosis. Kaplan-
Meier graph for the cumulative incidence of hepatocellular carcinoma (HCC)
according to the presence of bridging fibrosis or cirrhosis. The p value is based on
the log-rank test.
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Fig. 2. Incidence of hepatocellular carcinoma following sustained virological
response according to age among patients with cirrhosis. The incidence curves
for hepatocellular carcinoma (HCC) were constructed using the Kaplan-Meier
method. Twenty-four weeks after cessation of antiviral therapy was considered as
time 0. Statistical significance was assessed with the log-rank test.
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In nine patients, liver failure occurred either before the start of
therapy (n = 3), during therapy (n = 1) or after therapy but prior
to achievement of SVR (n = 5). After exclusion of these patients,
26 of the 991 remaining patients experienced liver failure during
follow-up (Table 2). Ascites was most frequently observed
(n = 13, 50.0%), followed by variceal bleeding (n = 7, 26.9%), hep-
atic encephalopathy (n = 2, 7.7%) and jaundice (n = 1, 3.8%). Three
(11.5%) patients had either ascites and/or encephalopathy, as
detailed data on the specific event was not available. None of
the patients with bridging fibrosis experienced liver failure.
Among patients with cirrhosis, the 8-year cumulative incidence
of liver failure was 4.1% (95% CI 2.3–5.9) (Fig. 3A). In three
(11.5%) of the patients with liver failure, the event occurred
within 6 months of the diagnosis of HCC or thereafter. Three
patients, all with HCC, underwent liver transplantation. During
the follow-up 56 (5.6%) patients died, which was registered to
be due to liver-related causes in 24 (42.8%) patients and due to
other causes in 25 (44.6%) patients (Table 2). For 7 (12.5%)
patients the cause of death was not known. The cumulative 8-
year all-cause mortality rate was 3.3% (95% CI 0.0–7.0) among
patients with bridging fibrosis vs. 9.6% (95% CI 6.7–12.5) among
patients with cirrhosis at baseline (Fig. 3B).
In total, 101 (10.2%) patients showed clinical progression of
their liver disease, resulting in a clinical disease progression rate
of 1.80 per 100 person-years (95% CI 1.47–2.20) (Table 2). The
first event was HCC in 47 (46.5%) patients, liver failure in 24488 Journal of Hepatology 201(23.8%) patients and death in 30 (29.7%) patients. The overall
cumulative 8-year clinical disease progression rate was 14.0%
(95% CI 11.1–16.9), which differed significantly among patients
with bridging fibrosis (4.2, 95% CI 0.1–8.3) as compared to
patients with cirrhosis (15.8, 95% CI 12.3–19.3) (Fig. 3C). Again,
patients with cirrhosis below the age of 45 at the start of success-
ful antiviral therapy showed a statistically significantly lower
incidence of events at 8 years of follow-up (7.9, 95% CI 2.4–
13.4) as compared to those between 45 and 65 years of age
(17.1, 95% CI 12.2–22.0) or those above the age of 65 (20.7, 95%
CI 12.3–29.1).
Cox regression analysis indicated that higher age, cirrhosis,
lower platelet counts, and lower albumin levels were indepen-
dently and significantly associated with clinical disease progres-
sion (Table 4). The associations between the variables and clinical
disease progression were proportional over time, and there were
no statistically significant interactions among the variables
included in the final model. The final multivariable Cox regres-
sion model showed similar results in the imputation analyses.Discussion
This is the first Western study among patients with chronic HCV
infection and advanced liver disease to assess the risk of
cirrhosis-related complications following achievement of SVR.
We found that the annual risk of HCC among patients with cir-
rhosis who cleared their HCV infection with IFN-based antiviral
therapy was almost 1%. The annual risk of cirrhosis-related mor-
bidity or mortality, as a combined endpoint, was twice as high.
The complications of advanced liver disease were more fre-
quently observed among patients who were older at the start of
successful antiviral therapy and among patients with more sev-
ere liver disease. As was previously described for patients with
cirrhosis and ongoing HCV infection, DMwas an independent risk
factor for HCC following SVR as well [26].
Since the HCV-infected population is aging and the proportion
of patients with more advanced liver disease is increasing, our7 vol. 66 j 485–493
Table 3. Cox proportional hazard analyses for hepatocellular carcinoma.
Hepatocellular carcinoma
Univariable analyses Multivariable analyses
(n = 630)#
Imputation analyses
(n = 1000)#
HR 95% CI p value HR 95% CI p value HR 95% CI p value
Age
<45 years 1.00 Ref. Ref. 1.00 Ref. Ref. 1.00 Ref. Ref.
45–60 years 5.13 1.57–16.79 0.007 8.54 1.13–64.64 0.038 9.68 1.28–72.95 0.028
>60 years 6.95 2.03–23.76 0.002 8.91 1.12–70.79 0.039 9.76 1.23–77.77 0.031
Males 1.28 0.69–2.38 0.426 - - - - - -
BMI, per 1.0 kg/m2 1.03 0.96–1.13 0.314 - - - - - -
Cirrhosis 2.94 0.91–9.42 0.071 - - - - - -
Laboratory markers of liver disease severity
Platelet count, per 10  109/L 0.93 0.88–0.98 0.005 0.94 0.87–1.00 0.048 0.93 0.87–0.99 0.029
Bilirubin, per mmol/L 1.01 0.99–1.04 0.233 - - - - - -
Albumin, per g/L 0.97 0.91–1.04 0.428 - - - - - -
AST/ALT ratio, per 0.1 1.04 1.00–1.08 0.046 1.04 1.00–1.09 0.084 1.04 1.00–1.09 0.068
gGT, per 10 IU/L 1.02 0.99–1.04 0.143 - - - - - -
Treatment naïve 0.39 0.22–0.71 0.002 - - - - - -
Diabetes mellitus 1.90 0.91–4.00 0.090 2.36 1.02–5.42 0.044 2.27 0.98–5.29 0.057
History of severe alcohol use 0.89 0.40–1.97 0.774 - - - - - -
Anti-HBc positive 1.16 0.60–2.25 0.655 - - - - - -
BMI, body mass index; HCV, hepatitis C virus; AST, aspartate aminotransferase; ALT, alanine aminotransferase; CI, confidence interval; gGT, gamma-glutamyltransferase;
antiHBc, anti-hepatitis B core antigen.
# The multivariable models were stratified by the median year of inclusion (2002).
JOURNAL OF HEPATOLOGYresults suggest that we will more frequently encounter HCC, liver
failure and liver-related mortality among patients with cured
HCV infection in the following years [5]. Although cirrhosis was
not statistically significantly associated with HCC in our cohort,
this is still likely to be an important risk factor. It is relevant to
consider that not all participating cohorts included patients with
bridging fibrosis, so that a lack of power may be of influence here.
The platelet count, which represents the extent of liver damage
and portal pressure, was significantly associated with HCC. Even
though the AST/ALT ratio fell just outside of the predefined a-
level in multivariable analyses, this readily available non-
invasive marker of hepatic fibrosis showed a strong trend for a
clinically relevant effect size. For this reason we kept the AST/
ALT ratio in our final model. The risk of clinical disease progres-
sion, of which more events could be registered, was statistically
significantly higher in case of cirrhosis rather than bridging fibro-
sis. Regardless of the severity of the HCV-induced liver disease,
the prevalence of insulin resistance is rapidly rising as well
[27]. Despite accumulation of these unfavorable prognostic char-
acteristics, improvements in antiviral therapy will enable us to
cure more patients. In fact, various IFN-free regimens have been
shown to cure approximately 95% of patients, whether or not cir-
rhosis is present [28–32]. Thus, it is highly relevant that physi-
cians are aware of the continuing health risks following
successful antiviral therapy among patients with HCV-induced
advanced liver disease.
An important message of our study is that patients with HCV-
related cirrhosis who have attained SVR should probably remain
included in HCC surveillance programs. Current AASLD guidelines
state that HCC surveillance is cost-effective in patients with hep-
atitis C if the annual risk exceeds 1.5% [3]. Although in our study
the overall risk among patients with cirrhosis and SVR did not
meet this cut-off, there are several reasons to justify why these
patients should be followed. First, the risk of HCC increased withJournal of Hepatology 201age and the population with cured HCV infection is rapidly aging.
In fact, patients who initiated their successful antiviral treatment
course above the age of 60 did meet the annual HCC risk cut-off of
1.5% as the HCC rate in this subgroup was 1.50 per 100 person-
years (data not shown). For patients who were younger at the
time of SVR it is possible that as they age the risk of HCC may
actually increase. Second, with the current effective and safe
IFN-free treatment regimens patients who are older and patients
with more advanced liver disease can be cured. Our data showed
that more advanced hepatic fibrosis (lower platelet count, higher
AST/ALT ratio and lower albumin level) were pre-treatment pre-
dictors of cirrhosis-related events following SVR. Also, given the
intrinsic antiproliferative properties of IFN, we cannot exclude
that the incidence of HCC will be higher among patients who
attained SVR with IFN-free regimens. Third, in case of SVR, the
potential gain in life-years following the diagnosis of HCC may
be higher due to reduced risk of other cirrhosis-related complica-
tions [11–13,15,33]. In a randomized controlled study among
patients with compensated HCV-induced cirrhosis and HCC, Shi-
ratori et al. found that the 7-year survival following tumor abla-
tion was 53% among those treated with IFN vs. 23% among
those not treated with IFN [34]. Within the IFN-treated group,
the survival at 7 years of follow-up was higher among patients
with SVR (68%) as compared to patients without SVR (47%). Sim-
ilar results were described in a retrospective study, which also
analysed hepatitis C patients with cirrhosis who underwent
IFN-based therapy prior to HCC development [35]. In this study
the cumulative survival was 93% among those with SVR and
57% among those without SVR at 6 years following HCC. Further
studies are required to determine the annual HCC risk cut-off for
cost-effective surveillance among patients with cirrhosis and
SVR.
In our study three patients with bridging fibrosis and SVR
were diagnosed with HCC. Among these patients there was no7 vol. 66 j 485–493 489
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Fig. 3. Incidence of liver failure, all-cause mortality and clinical disease
progression following sustained virological response according to the pres-
ence of bridging fibrosis or cirrhosis. The incidence curves for liver failure (A),
all-cause mortality (B) and clinical disease progression (C) were constructed using
the Kaplan-Meier method. Clinical disease progression was defined as the
occurrence of liver failure, hepatocellular carcinoma, liver transplantation or
death. Twenty-four weeks after cessation of antiviral therapy was considered as
time 0. Statistical significance was assessed with the log-rank test.
Research Articleclear evidence for other causes of liver injury. In one patient,
however, the interval between the pre-treatment liver biopsy
and the initiation of antiviral therapy was rather long (3.8 years)
so that progression to cirrhosis cannot be excluded. In fact, the490 Journal of Hepatology 201platelet counts were low in all three patients, which might sug-
gest underestimation of severity of liver disease due to sampling
error [36]. Nevertheless, cases of HCC have been previously
reported in Western patients with chronic HCV infection without
cirrhosis following SVR [37]. Although it cannot be excluded that
successfully treated patients with bridging fibrosis may develop
HCC, their risk seems to be low. Before deciding to discharge
the individual patient with bridging fibrosis and SVR from further
follow-up, physicians should take secondary markers of liver dis-
ease severity into account to ensure that the patient had not pro-
gressed to cirrhosis since the pre-treatment hepatic fibrosis
assessment.
Although this is the first study to assess the incidence of HCC
among a large cohort of patients with HCV-induced advanced
fibrosis and SVR, previous studies have evaluated risk factors of
HCC following SVR. Yet, all these studies were performed in East
Asia and included predominantly patients without advanced liver
disease [38–46]. Still, the reported cumulative HCC incidences
were relatively high, with 5-year rates ranging from 1.5 to
approximately 6%. Advanced hepatic fibrosis was an important
universal risk factor for development of HCC following SVR in
these studies. In this subgroup the cumulative HCC incidence ran-
ged from 9 to 15.6% after 5 years of follow-up. Genetic differ-
ences, the earlier wave of HCV infection, the higher prevalence
of hepatitis B virus and a higher dietary exposure to alcohol or
aflatoxin through Aspergillus-contaminated food products in Asia
are possible explanations for this epidemiological difference in
HCC occurrence between the East and the West [47,48]. Our
study is novel as it specifically assesses the residual risk of
HCC, its pattern of development over time and specific risk fac-
tors following SVR in the subgroup of patients with cirrhosis from
the West. We found age, severity of liver disease and diabetes to
be associated with HCC occurrence among patients with
advanced liver disease and SVR.
It will probably remain difficult to accurately identify patients
with cirrhosis and SVR who have a sufficiently low risk of HCC to
be discharged from further follow-up. Pre-treatment predictors
may not suffice as there are many factors following SVR which
can influence a patient’s risk. Even though the current data might
suggest that patients with cirrhosis below the age of 45 may not
require surveillance following SVR, it remains unknown whether
their risk of HCC will increase as they age. Future studies need to
assess the predictive accuracy of post-treatment markers and
their kinetics during follow-up, as a recent study indicated that
regression of hepatic fibrosis following antiviral therapy among
patients with cirrhosis was associated with improved clinical
outcome [21]. A history of alcohol abuse was not associated with
HCC or clinical disease progression in the current cohort.
Although we cannot exclude the possibility that heterogeneity
of the gathered data or missing data may be partly responsible
for these lacking associations, it should also be considered that
all included patients underwent IFN-based therapy which is not
generally administered to those with severe alcohol abuse. Data
on alcohol use following successful antiviral therapy were not
available in our cohort. It may be expected, however, that
continuous alcohol abuse increases the risk of cirrhosis-related
complications among patients with advanced liver disease and
SVR as well, so that also these patients should be advised to limit
their alcohol intake [49,50]. Non-alcoholic fatty liver disease or
new hepatotrophic infectious agents also represent plausible
causes of continuing hepatic inflammation which may drive7 vol. 66 j 485–493
Table 4. Cox proportional hazard analyses for clinical disease progression.
Clinical disease progression
Univariable analyses Multivariable analyses (n = 785)# Imputation analyses (n = 991)#
HR 95% CI p value HR 95% CI p value HR 95% CI p value
Age
<45 years 1.00 Ref. Ref. 1.00 Ref. Ref. 1.00 Ref. Ref.
45–60 years 2.68 1.41–5.12 0.003 1.81 0.87–3.76 0.112 2.08 1.08–4.01 0.028
>60 years 3.60 1.81–7.16 <0.001 2.54 1.17–5.49 0.018 2.75 1.37–5.55 0.005
Males 1.21 0.79–1.86 0.390 - - - - - -
BMI, per 1.0 kg/m2 1.02 0.96–1.09 0.465 - - - - - -
Cirrhosis 2.94 1.29–6.73 0.010 2.99 1.05–8.51 0.040 2.78 1.17–6.63 0.021
Laboratory markers of liver disease severity
Platelet count, per 10  109/L 0.92 0.89–0.96 <0.001 0.95 0.91–0.99 0.020 0.95 0.91–1.00 0.040
Bilirubin, per mmol/L 1.02 1.00–1.03 0.012 - - - - - -
Albumin, per g/L 0.93 0.90–0.97 0.002 0.94 0.90–0.99 0.018 0.94 0.90–0.99 0.016
AST/ALT ratio, per 0.1 1.04 1.01–1.06 0.006 - - - - - -
gGT, per 10 IU/L 1.02 1.00–1.03 0.079 - - - - - -
Treatment naïve 0.71 0.47–1.07 0.050 - - - - - -
Diabetes mellitus 1.60 0.94–2.72 0.085 - - - - - -
History of severe alcohol use 0.80 0.44–1.45 0.464 - - - - - -
AntiHBc positive 1.09 0.68–1.77 0.715 - - - - - -
BMI, body mass index; HCV, hepatitis C virus; AST, aspartate aminotransferase; ALT, alanine aminotransferase; CI, confidence interval; gGT, gamma-glutamyltransferase;
antiHBc, anti-hepatitis B core antigen.
# The multivariable models were stratified by the median year of inclusion (2002) and adjusted for the type of interferon.
JOURNAL OF HEPATOLOGYcarcinogenesis following HCV eradication. Future studies need to
assess their contribution to the outcome of patients with SVR in
more detail.
Because the clinical efficacy of antiviral therapy is highest
among those with advanced liver disease, costly new treatment
regimens are mostly limited to this subgroup which is at highest
risk of cirrhosis-related events [51]. The data presented here
actually suggest that we should pursue successful antiviral ther-
apy prior to the stage of advanced fibrosis. This can save the costs
of both HCC surveillance as well as the cirrhosis-related compli-
cations. It might thus be worthwhile not to neglect patients with
lesser stages of hepatic fibrosis, especially those prone to pro-
gress to cirrhosis [52].
Our study has several limitations. As data were combined
from previously published cohorts from multiple countries, some
heterogeneity regarding the collected data could not be pre-
vented. On the other hand, the participating cohort studies had
rather similar inclusion and exclusion criteria and comparable
follow-up designs. The fact that many countries are represented
in this combined cohort makes the presented estimates applica-
ble to a broad spectrum of patients as well. Still, databases dif-
fered and there was missing data for some variables. We have
therefore performed imputation analyses to check the stability
of the estimated hazard ratios. Methodological differences
between the participating cohorts with respect to data collection
were an important reason for missing data in our study, however,
as not all cohorts registered all the variables which were included
in our analyses. As a result, possible bias due to missing data
which might not be missing at random may be limited. Unfortu-
nately, data regarding the evolution of liver disease during
follow-up or at the time of HCC were not available, which might
be relevant in order to differentiate patients with SVR who
remain at risk for the cirrhosis-related complication from those
who are no longer at risk. Also, because the cohort studies that
were part of this analysis had retrospective designs, it is possible
that some events may have been missed. This would tend to biasJournal of Hepatology 201our estimates to a lower rate of HCC, however, and thus only
increase the need for ongoing surveillance. Finally, because all
patients in this cohort were eligible to be treated with IFN-
based therapy, the patients included here had advanced but clin-
ically stable liver disease. While our data suggest that patients
with more advanced cirrhosis prior to SVR are at higher risk of
cirrhosis-related complications, future studies should assess the
clinical outcome among those with Child-Pugh score B and C
who are now successfully treated with the IFN-free regimens.
To conclude, patients with chronic HCV infection and
advanced fibrosis who have attained SVR remain at risk of HCC
and other cirrhosis-related complications. Preferably, patients
should thus be cured of their HCV infection prior to the develop-
ment of advanced hepatic fibrosis. In case this is not accom-
plished, it is important to consider continued HCC surveillance
upon achievement of SVR.Financial support
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